Skip to main content
PEN
NYSE Industrial Applications And Services

Penumbra to be Acquired by Boston Scientific for $14.5 Billion, Offering Significant Premium

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
10
Price
$355.74
Mkt Cap
$12.275B
52W Low
$221.26
52W High
$325.025
52W Position info
61% above low
Off High info
at 52W high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

PEN sits 61% above its 52-week low of $221.26 on elevated volume (1.8× avg).

Summary

Penumbra Inc. has entered into a definitive agreement to be acquired by Boston Scientific Corporation for an enterprise value of approximately $14.5 billion, or $374 per share, representing a substantial premium for shareholders.


Key Events · M&A and Partnerships · PEN

  • Acquisition Agreement

    Boston Scientific Corporation will acquire Penumbra Inc. for an enterprise value of approximately $14.5 billion.

  • Shareholder Value

    Penumbra shareholders will receive $374 per share, a notable premium to the current trading price of $355.74 and the 52-week high of $325.025.

  • Consideration Mix

    The transaction is structured as approximately 73% cash and 27% Boston Scientific common stock.

  • Strategic Expansion

    The acquisition will significantly expand Boston Scientific's cardiovascular portfolio, particularly in mechanical thrombectomy and neurovascular segments.


Analysis · PEN · Industrial Applications And Services

This acquisition is a transformative event for Penumbra, providing shareholders with a significant premium over the current market price and the company's 52-week high. The transaction, valued at $14.5 billion, will integrate Penumbra's innovative vascular and neurovascular solutions into Boston Scientific's portfolio, expanding its market reach in fast-growing segments. The consideration is a mix of cash and stock, with Penumbra's CEO electing to receive Boston Scientific shares and joining their board, signaling confidence in the combined entity's future. Investors should note the expected dilution to Boston Scientific's adjusted EPS in the first year, followed by accretion.

At the time of this filing, PEN was trading at $355.74 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.3B. The 52-week trading range was $221.26 to $325.03. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PEN - Latest Insights

PEN
Jun 15, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $319.06
Real-time Price: $320.26 info
Change: +$1.20 (+0.38%) info
Market Cap: $12.596B info
PEN
Jun 11, 2026, 4:05 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $318.32
Real-time Price: $320.26 info
Change: +$1.94 (+0.61%) info
Market Cap: $12.596B info
PEN
May 07, 2026, 9:01 AM EDT
Filing Type: 425
Importance Score:
8
Price at Filing: $323.86
Real-time Price: $320.26 info
Change: -$3.60 (-1%) info
Market Cap: $12.596B info
PEN
May 07, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $323.86
Real-time Price: $320.26 info
Change: -$3.60 (-1%) info
Market Cap: $12.596B info
PEN
May 06, 2026, 4:49 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $324.19
Real-time Price: $320.26 info
Change: -$3.93 (-1%) info
Market Cap: $12.596B info